Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS4723028 A
Type de publicationOctroi
Numéro de demandeUS 06/753,037
Date de publication2 févr. 1988
Date de dépôt8 juil. 1985
Date de priorité7 juil. 1984
État de paiement des fraisCaduc
Autre référence de publicationDE3524199A1
Numéro de publication06753037, 753037, US 4723028 A, US 4723028A, US-A-4723028, US4723028 A, US4723028A
InventeursKoichi Shudo
Cessionnaire d'origineKoichi Shudo
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Stilbene derivatives
US 4723028 A
Résumé
The application discloses certain stilbene compounds, pharmaceutical compositions thereof, method of treating thereof, method of diagnosis therewith, and method for the preparation thereof. The compounds and compositions are useful for diagnosis of leukemia types, the treatment of dermatological disorders, and as differentiation-inducing agents for neoplastic cells.
Images(9)
Previous page
Next page
Revendications(14)
What is claimed is:
1. A stilbene compound represented by the formula (I): ##STR10## wherein R1 and R2 each independently represents hydrogen, lower alkyl, or cycloalkyl, with the proviso that both R1 and R2 cannot be hydrogen simultaneously, R3 and R4 independently represent hydrogen, methyl, or trifluoromethyl, and R5 represents hydroxyl, lower alkoxyl, or lower alkylamino of the formula --NR6 R7, wherein R6 and R7 each independently represents hydrogen or lower alkyl.
2. A compound according to claim 1, wherein R1 represents isopropyl, cyclopropyl, or butyl.
3. A compound according to claim 1, wherein R1 and R2 each represents ethyl or isopropyl.
4. A compound according to claim 1, wherein R3 and R4 each represents hydrogen, methyl, or trifluoromethyl.
5. A compound of claim 1 which is [E-2-(3,4-di-isopropylphenyl)propenyl]benzoic acid.
6. A compound of claim 1 which is [E-2-(3-tert.-butylphenyl)ethenyl]benzoic acid.
7. Method for diagnosis to determine the type of leukemia which comprises the incubation of the blood of a patient with leukemia in vitro in the presence of a compound of claim 1, and the observation of morphological changes and/or of colony formation of the leukemia cell.
8. Use of one or more stilbene derivatives of claim 1 as medicaments for treatment of dermatological disorders of humans and animals.
9. A differentiation-inducing agent for neoplastic cells, especially leukemia cells, comprising as active ingredient one or more stilbene compounds of claim 1.
10. A compound of claim 1, which is [E-2-(4-tert.-butylphenyl)-3,3,3-trifluoropropenyl]-benzoic acid.
11. A compound of claim 1 which is [E-2-(3-cyclopropyl-phenyl)-ethenyl]benzoic acid.
12. A process for preparation of a stilbene represented by the formula (I): ##STR11## wherein R1 and R2 each independently represents hydrogen, lower alkyl or cycloalkyl, with the proviso that both R1 and R2 cannot be hydrogen simultaneously, R3 and R4 independently represent hydrogen, methyl, or trifluoromethyl, and R5 represents hydroxyl, lower alkoxyl, or lower alkylamino of the formula --NR6 R7, wherein R6 and R7 each independently represents hydrogen or lower alkyl, which comprises reacting a compound represented by the formula (II) ##STR12## wherein R1, R2 and R3 have the meanings previously assigned, with a compound represented by the formula (III) ##STR13## wherein R5 has the meaning previously assigned and X represents a group represented by the formula: ##STR14## wherein R4 has the meaning previously assigned and Y is an anion of an organic or inorganic acid or a dialkoxyphosphonylalkyl group represented by the formula: ##STR15## wherein R4 has the value previously assigned and R represents a lower alkyl group and, if desired, converting the carboxylic acid ester group represented by the formula --COR5 into the carboxylic acid group or a carbamide group.
13. Compound of claim 1 which is [E-2-(3,4-diethylphenyl)propenyl]benzoic acid.
14. Compound of claim 1 which is [E-2-(3,4-diethylphenyl)propenyl]benzoic acid methyl ester.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention

Some chondrogenetic disorders and dermatological disorders such as psoriasis and malignant disorders such as leukemia can be looked upon as a disease involving a block or an abnormality in differentiation. The present invention relates to novel organic compounds which have great potential as useful medicaments and which may accordingly be developed and offered for treating the disorders of humans and animals.

Further the compounds of the prevent invention can be used for diagnosis of leukemia.

The present invention relates to novel organic compounds which have great potential as useful medicaments and which may accordingly be developed and offered for therapeutical use in the field of cancer chemotherapy.

2. Description of the Prior Art

It is already known that an interesting method exists, by which the differentiation of cancer cells is effected and an extinction of cancer cells caused to occur (J. Med. Chem. 25 1269-1277 (1982) with Title: Retinoids at the Threshold: Their Biological Significance and Therapeutic Potential; Cancer Research (Suppl.) 43 2469s-2475s May 1983 with Title: Inhibition of Carcinogenesis by Retinoids; BLOOD of J.A.S. of Hematology 62 709-721 (1983) with Title: Induction of Differentiation of Human Acute Myelogenous Leukemia Cell; Therapeutic Implications; Experientia 34 1105-1246 1978: with Title: Retinoids, a new class of compounds with prophylactic and therapeutic activities in oncology and dermatology and Cell Technology 2, No. 12 (1983)). This literature reports also that retinoic acid, retinoids, and related compounds have significant therapeutic potential in oncology and dermatology.

In the specification of DOS No. 28 54 354, it is reported that stilbene derivatives such as p-((E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl)-benzylmethyl ether are pharmacologically valuable and useful for systemic and topical treatment and prophylaxis of benign or malignant tumors. These compounds and retinoids are said to be suitable for systemic and topical treatment of acne, psoriasis and precancerous conditions and for other dermatopathy which is accompanied by hyperkeratinization as well other pathologic and allergic dermatological disease.

DETAILED DESCRIPTION OF THE INVENTION

It has now been found that the compounds of the formula (I): ##STR1## wherein R1 and R2 each independently represents hydrogen, lower alkyl, or cycloalkyl, with the proviso that both R1 and R2 cannot be hydrogen simultaneously, R3 and R4 represent hydrogen, methyl, or trifluoromethyl, and R5 represents hydroxyl, lower alkoxyl, lower alkylamino of the formula --NR6 R7 (wherein R6 and R7 represent hydrogen or lower alkyl), are capable of inducing the differentiation of malignant cells, especially leukemia cells, both morphologically and functionally, and can therefore be used in the therapy of malignant diseases in accord with the aforesaid third method.

By the term "lower" in formula I is meant a straight or branched carbon chain having 1-6 carbon atoms. Therefore, the lower alkyl moiety of the lower alkyl, lower alkoxy, and lower alkylamino group encompassed by R1, R2, R5, R6 and R7 is representatively methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, etc. The lower alkoxy moiety of the lower alkoxy group is representatively methoxy, ethoxy, propoxy, butoxy, etc., and the lower alkylamino group is representatively mono- or dimethylamino, mono- or diethylamino, etc.

By cycloalkyl there is representatively intended cyclopropyl, cyclobutyl, methylcyclopropyl, and the like.

Moreover, the compounds of this invention may be of either or both of the trans and cis types.

The compounds of above-shown general formula I provided by this invention form salts with bases. This invention includes the pharmaceutically-acceptable salts of the compounds of general formula I, and examples of these salts are the salts with alkali metals such as sodium, potassium, etc., or alkaline earth metals such as calcium, etc.; the salts with ammonia; and the salts with organic bases such as methylamine, ethylamine, diethylamine, trimethylamine, triethylamine, pyridine, picoline, arginine, lysine, etc.

The compounds of this invention have been tested according to established test procedure which shows the differentiation of malignant cells, whereby the differentiation of human acute promyelocytic leukemia cells (HL-60) and their conversion to granulocytes (myelocytes) can be assayed by an observation of the morphological changes of nuclei and by the measurement of the degree of reduction of nitro-blue tetrazolium (NBT) which is induced by a test compound (Proc. Natl. Acad. Sci. USA 77, 2936-2940 (1980) with Title: Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid).

The HL-60 cell are cultured in plastic flasks in RPMI-1640 medium supplemented with 5% heat inactivated fetal calf serum and antibiotics (penicillin G and streptomycin). The cells (3×104 /ml) were cultured with a compound of the present invention for 4 days. Growth inhibition of the cells by the test compounds was determined by counting the number of cells by microscope and relative ratio was examined by taking the number of cells by control (without test compound) as 100%. The cells are fixed and stained with Wright-Giemsa to examine the morphological changes of the nuclei.

The cells treated with the present compounds are differentiated to mature granulocytes (myelocytes, metamyelocytes and neutrophiles), just as the cells treated with retinoic acid.

The biochemical activity of cells treated with the compound was measured as follows:

The cells after 5 days incubation are centrifuged and diluted with RPMI-1640 medium supplemented with 5% fetal calf serum, to provide a definite number of the cells. To the diluted cell suspension are then added 200 ng/ml of 12-o-tetradodecanoylphorbol-13-acetate (TPA), and the resulting culture medium is then incubated for 20 minutes at 37° C. in the presence of 0.1% of NBT. Thus, the mature differentiated cells containing blue-black formazan is counted by microscopy, so that the ratio of the cells having the ability to reduce NBT, to total cells, can be calculated.

The cells treated with the compound of this invention show the NBT reduction activity which corresponds to the important biochemical activity of differentiated cells.

The results of the tests according to the above-mentioned methods are summarized in Table 2.

As can be seen from the results shown in Table 2 the activity of the compounds of this invention is observed at a concentration below 10-6 Mol. Those compounds, wherein R1 and R2 are both ethyl, isopropyl or t-butyl, or wherein R1 or R2 at the meta position is t-butyl, are most active and indeed at concentrations between 10-8 and 10-9.

The alkyl-substitution R1 and R2 on the phenyl group in the formula (I) is a characteristic of the stilbene-4-carboxylic acids and their derivatives which are the compounds of this invention. Such a compound, wherein the alkyl group is a middle alkyl group, especially wherein R1 is an isopropyl, cyclopropyl, cyclobutyl, or butyl group, or wherein R1 and R2 are both an ethyl, isopropyl or tert-butyl group, is effective. On the other hand such a compound, wherein R1 and R2 are both hydrogen, does not exhibit the desired activity.

The compounds of the formula (I), wherein R3 and R4 represent hydrogen, methyl, or trifluoromethyl, are especially effective.

Since the compounds of the present invention differentiate the leukemia cells to mature granulocytes morphologically and functionally and inhibit the cells-growth potentially, those can be used as medicines to use for treatment of humans and animals with cancer and dermatological disorders, and further as diagnosis for determining the type of leukemia by a measuring method, whereby the blood of a patient with leukemia is incubated in vitro in the presence of a present compound in an Onalogious manner as described in the morphological assay for the HL-60 cells: Only promyelocytic leukemia cells, but not lymphocytic leukemia cells, differentiate to mature granulocytes which can be clearly determined by microscope (See: Saibo (Cells) 14 533 (1982)).

When the incubation is performed in a soft agar, promyelocytic leukemia cells do not form a colony, since the differentiated cells do not proliferate further.

Thus, these compounds are very useful in the determination of promyelocytic leukemia, which enables one to select the therapeutical methods.

These compounds suppress the hyperkera keratinization of human tissue cells, and are useful for the treatment of cystic acne, psoriasis and related cutaneous disorders of keratinization and of epithelial differentiation.

The medical compositions containing the compounds of this invention as the main component are formulated by a conventional manner using conventional carriers for formulation and excipients. The medicaments may be administered orally as tablets, pills, capsules, granules, etc., or may be administered parenterally as injections such as intraveous injections, intramuscular injections, etc., in the form of an ointment, cream, and the like for external application or as aerosols, suppositories, etc. The doses of the medicaments are properly determined according to each case on considering the symptom, the age of patient, sex distinction, etc., but are usually 1-100 mg per day for adult in case of oral administration and 1-50 mg per day for adult in case of parenteral administration, which is administered in 2-3 times a day.

The stilbene derivatives represented by the formula (I) ##STR2## wherein R1 and R2 each independently represents hydrogen, lower alkyl, or cycloalkyl, with the proviso that both cannot be hydrogen simultaneously, R3 and R4 represent hydrogen, methyl, or trifluormethyl, and R5 represents hydroxyl, lower alkoxyl, or a group of the formula --NR6 R7 (wherein R6 and R7 are hydrogen or lower alkyl), can be prepared by the reaction of a compound represented by the formula (II) ##STR3## wherein R1, R2 and R3 have the same meanings as given previously, with a compound represented by the formula (III) ##STR4## wherein R5 has the same meaning as presiously assigned and X represents a group having the formula: ##STR5## (wherein R4 has the meaning previously assigned and Y is the anion of an organic or inorganic acid) or a dialkoxyphosphonylalkyl group having the formula: ##STR6## (wherein R4 has the meaning previously given and R represents a lower alkyl group) and, if necessary or desirable, converting the carboxylic acid ester group represented by the formula --COR5 into the carboxylic acid group or the carbamide group.

The following examples are given by way illustration only and are not to be construed as limitations of this invention.

EXAMPLE 1 ##STR7## Step (a) Bromination of butyltoluene

A solution of 400 mg (2.7 mmole) of m-tert. butyltoluene, 540 mg (3.03 mmole) of N-bromsuccinic imide and 50 mg of azoisobutylnitrile in 10 ml of chloroform was heated under reflux for 2 hours. After completion of the reaction, the insoluble substances were removed by filtration and the solvent was distilled off to give the bromide (yield: 98%).

Step (b)

640 mg (2.82 mmole) of m-tert.-butylbenzylbromide obtained in Step (a) and 660 mg (2.52 mmole) of triphenylphosphine were disolved in 7 ml of benzene and the resulting solution was heated under reflux for 5 hours. After completion of the reaction, the precipitated crystals were removed by filtration to give the phosphonium bromide (yield: 68.2%).

Step (c) Wittig Reaction

To a solution of 634 mg (1.29 mmole) of phosphoniumbromide and 216 mg (1.32 mmole) of terephthalaldehyde methyl ester in 15 ml of anhydrous methanol was added 80 mg (1.48 mmole) of sodium methylate, and the resulting mixture was stirred at room temperature for one night. The precipitate (trans form) was removed by filtration. Further, by chromatography of the filtrate containing both the trans and cis forms, further compound in the trans form was be obtained (yield 50%).

Step (d) Hydrolysis

To a solution of 50 mg (0.16 mmole) of methylester obtained in Step (c) in 3 ml ethanol was added 5 ml of 1N-sodium hydroxide and the resulting solution heated under reflux for 2 hours. After completion of the reaction, the solution was rendered acidic with dilute aqueous hydrochloric acid solution and extracted with ethyl acetate. The ethyl acetate layer was washed with water until the pH of the washings reached 7, dried over anhydrous sodium sulfate, and solvent distilled off to give the carboxylic acid having a melting point of >300° C. (yield 98%).

Elemental Analysis for C19 H20 O2 : Calcd. C; 81.39, H; 7.19, Found C; 81.32, H; 7.20.

EXAMPLE 2 ##STR8## Step (a) Acetylation by Friedel-Craft

To a suspension of 5.0 g (37.3 mmole) of o-diethylbenzene and 3.2 g (40.7 mmole) of acetyl chloride in 30 ml of 1,2-dichlorethane was slowly added 5.7 g (42.7 mmole) of aluminum chloride at a temperature of 0° C. After the addition was complete, the mixture was stirred additionally for one hour. After completion of the reaction, the reaction product was poured over ice and extracted with ether.

The resulting organic layer was washed successively by with 1N-sodium bicarbonate, water, saturated aqueous saline solution, and dried over anhydrous sodium sulfate.

The solvent was removed to yield the acetyl product (yield 62.1%), which was purified by distillation to give the pure product having a boiling point of 110°-112.5° C./2.5 mmHg.

Step (b) Reduction

To a solution of 4.08 g (23.1 mmole) of 3,4-diethylacetophenone in 15 ml of methanol was slowly added 570 mg (15.1 mmole) of sodium borohydride at a temperature of 0° C.

After addition was complete, the mixture was stirred for 1.5 hours. After completion of the reaction, the reaction product was poured over a mixture of ice and dilute aqueous hydrochloric acid solution and extracted with ether. The ether layer was washed successively with 1N sodium bicarbonate, water, and aqueous saline solution and dried over anhydrous sodium sulfate. The solvent was distilled off to yield the alcohol product (yield 86.3%), which was purified by distillation to give the pure product having a boiling point of 114°-115° C./2.5 mmHg.

Step (c) Bromination

To a mixture of 3 ml of ether and 30 ml of hexane was added with stirring 3.56 g (19.9 mmole) of the alcohol product obtained in Step (b) and 2 drops of pyridine. To the resulting solution was slowly added a solution of 1.05 ml of phosphorus tribromide in 10 ml of hexane at temperature of 0° C. After the addition was complete, the solution was stirred additionally for 1.5 hours. After the reaction was complete, the reaction product was poured over ice and extracted with ether. The organic layer was washed successively with 1N-sodium bicarbonate, water and aqueous saline solution, dried over sodium sulfate, and the solvent distilled off at low temperature to give the bromide product (yield 95.8%), which was used in the following Step (d) without purification.

Step (d)

A solution of 4.612 g (19.1 mmole) of the bromide product and 4.993 g (19.0 mmole) of triphenylphosphine in 30 ml of benzene was heated under reflux for 24 hours. After the reaction was complete, the reaction solution was allowed to cool to room temperature. The precipitate was isolated by filtration. Concentration of the filtrate and chromatography through a silica gel column gave further phosphonium bromide (yield 64.7%).

Step (e) Wittig Reaction

A solution of 4.8 g (9.53 mmole) of the phosphonium bromide and 1.56 g (9.51 mmole) of terephthalaldehyde acid methyl ester in 40 ml butylene oxide was heated in a stream of argon under reflux for 24 hours. After the reaction was complete, the reaction solution was concentrated. Chromatography on a silica gel column and recrystallization gave the methyl ester product in the trans form having a melting point of 50°-50.5° C. (yield 71%).

Step (f) Hydrolysis

To a solution of 98 mg (0.29 mmole) of the methylester obtained in Step (e) in 5 ml of ethanol was added 5 ml of 1N sodium hydroxide and the resulting solution was heated under reflux for two hours. After reaction was complete, the solution was rendered acidic with dilute aqueous hydrochloric acid solution and extracted with ethyl acetate. The ethyl acetate layer was washed with water, until the pH of the washings reached 7, and dried over anhydrous sodium sulfate. The solvent was removed to give the carboxylic acid having a melting point of 193°-193.5° C. (yield 95%).

Elemental Analysis for C20 H22 O2 : Calcd.: C; 81.60, H; 7.53, Found: C; 81.59, H; 7.64.

EXAMPLE 3 ##STR9## Step (a) Trifluoroacetylation

To a mixture of 5.0 g t-butylbromobenzene (23.5 mmole) with 50 ml of dried ether was added 570 mg metallic magnesium (23.5 mmole), and the resulting mixture was heated in a stream of argon under reflux for 30 minutes.

To the reaction mixture was slowly added 0.6 ml trifluoroacetylchloride under ice-cooling. After the addition was complete, the reaction mixture was heated under reflux for two hours, poured over ice, and extracted with ether. The ether layer was washed successively with 1N sodium bicarbonate, water, saturated aqueous saline solution, and dried over anhydrous sodium sulfate. Distillation and chromatography through a silica gel column gave the desired product (yield 20.0%).

Step (b) Wittig Reaction

A suspension of 15 mg (0.04 mmole) of 18-crown-6 ether and 500 mg of (8.61 mmole) of potassium fluoride (anhydride) in 5 ml of anhydrous acetonitrile was stirred for 20 minutes at room temperature in a stream of argon. The reaction solution was heated at 70° to 80° C. and a suspension of 100 mg of p-tert.-butyl α,α,α-trifluoroacetophenone and 213 mg of phosphonium salt (prepared from 4-bromomethylbenzoic acid methyl ester and triphenylphosphine) in acetonitrile was added thereto all at one time. Then, 2-3 hours after addition, the reaction solution was filtered and concentrated to give a mixture of the desired methyl ester compound in trans and cis forms (yield 88.3%, trans/cis=1:7). Silica gel chromatography gave the pure trans compound (yield 10%).

Step (c) Hydrolysis

To a solution of 40 mg (0.11 mmole) of the methyl ester in 2 ml of ethanol was added 3 ml of 1N sodium hydroxide under reflux over a period of two hours. After reaction was complete, the reaction mixture was acidified with dilute aqueous hydrochloric acid solution and extracted with ethyl acetate. The ethyl acetate layer was washed with water until the pH of the washings reached 7, and dried over anhydrous sodium sulfate. The solvent was removed to give the carboxylic acid having a melting point of 182°-183° C. (yield 69.4%). MASS: M+ 348 (calcd. C20 H19 F3 O2 =348)

As described in the foregoing Examples 1-3, further compounds of Table I have been prepared. In the column of synthesis in Table I is stated the number of the corresponding Example, according to which each compound is prepared.

              TABLE 1______________________________________                                       syn-                                       the-R.sub.1  R.sub.2  R.sub.3                    R.sub.5                         mp     Anal   sis______________________________________ 1  CH.sub.3 CH.sub.3 CH.sub.3                      CH.sub.3                           93-94  C.sub.19 H.sub.20 O.sub.2                                         2 2  "        "        "    H    213-215                                  C.sub.18 H.sub.18 O.sub.2                                         2 3  C.sub.2 H.sub.5        C.sub.2 H.sub.5                 "    CH.sub.3                           50-50.5                                  C.sub.21 H.sub.24 O.sub.2                                         2 4  "        "        "    H    193-194.5                                  C.sub.20 H.sub.22 O.sub.2                                         2 5  isoC.sub.3 H.sub.7        isoC.sub.3 H.sub.7                 "    H    236.5-237                                  C.sub.22 H.sub.26 O.sub.2                                         2 6  t-Bu     H        H    H    >300   C.sub.19 H.sub.20 O.sub.2                                         1 7  H        t-Bu     H    H    213.5-215                                  C.sub.19 H.sub.20 O.sub.2                                         1 8  "        "        "    CH.sub.3                           104.5-105                                  C.sub.21 H.sub.24 O.sub.2                                         2 9  "        "        CH.sub.3                      H    243-244.5                                  C.sub.20 H.sub.22 O.sub.2                                         210  "        "        CF.sub.3                      H    182-183                                  M.sup.+ 348                                         311  C.sub.3 H.sub.5        H        CH.sub.3                      H    210-220                                  C.sub.19 H.sub.18 O.sub.2                                         2______________________________________

                                  TABLE 2__________________________________________________________________________              Myelocytes                      Banded and  Growth              and     Segmented                            Reductivity                                  inhibitationCompound Concent.      Promyelocytes              Metamyelocytes                      neutrophils                            of NBT                                  of cells(No.) (M)  (%)     (%)     (%)   (%)   (%)__________________________________________________________________________Blank --   98       2      0      0    100Retinoic 10.sup.-7      25      71      4     75    32acid1     10.sup.-6      90      10      0      5    922     10.sup.-6      81      18      1      8    783     10.sup.-9      40      53      7     40    654     10.sup.-9      27      58      15    76    305     10.sup.-9      35      58      8     76    186     10.sup.-8      46      31      3     56    217     10.sup.-6      80      19      1     11    318     10.sup.-7      60      34      6     15    339     10.sup.-7      66      32      2     11    3310    10.sup.-7      90      10      0      2    7011    10.sup.-8      40      52      8     61    29__________________________________________________________________________
Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
DE2854354A1 *15 déc. 19785 juil. 1979Hoffmann La RocheStilbenderivate, verfahren und zwischenprodukte zu ihrer herstellung und arzneimittel
Citations hors brevets
Référence
1 *Breitman T. R., et al., Induction of Differentiation of the Human Promyelocytic Leukemia Cell Line (HL 60) by Retinoic Acid, Proc. Natl. Acad. Sci., 77, 2936 2940, (1980).
2Breitman T. R., et al., Induction of Differentiation of the Human Promyelocytic Leukemia Cell Line (HL-60) by Retinoic Acid, Proc. Natl. Acad. Sci., 77, 2936-2940, (1980).
3 *Chemica Therapeutica, Jan. Feb., 1980 15, No. 1, pp. 9 15; Arotinoids, A New Class of Highly Active Retinoids , by Peter Loeliger, et al.
4Chemica Therapeutica, Jan.-Feb., 1980-15, No. 1, pp. 9-15; "Arotinoids, A New Class of Highly Active Retinoids", by Peter Loeliger, et al.
5 *Koeffler P., Induction of Differentiation of Human Acute Myelogenous Leukemia Cells: Therapeutic Implications, J. Am. Soc. Hematology, 62, 709 721, (1983).
6Koeffler P., Induction of Differentiation of Human Acute Myelogenous Leukemia Cells: Therapeutic Implications, J. Am. Soc. Hematology, 62, 709-721, (1983).
7 *Mayer, et al., Retinoids, a New Class of Compounds with Prophylactic and Therapeutic Activities in Oncology and Dermatology, Experientia, 34, 1105 1119, (1978).
8Mayer, et al., Retinoids, a New Class of Compounds with Prophylactic and Therapeutic Activities in Oncology and Dermatology, Experientia, 34, 1105-1119, (1978).
9 *Moon, R. C. et al., Inhibition of Carcinogenesis by Retinoids, Cancer Research Suppl., 43, 2469s 2475s, (1983).
10Moon, R. C. et al., Inhibition of Carcinogenesis by Retinoids, Cancer Research Suppl., 43, 2469s-2475s, (1983).
11 *Pawson, et al., Retinoids at the Threshold: Their Biological Significance and Therapeutic Potential, J. Med. Chem., 25, 1269, 1277, (1982).
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US4857658 *17 déc. 198715 août 1989Basf AktiengesellschaftPreparation of (Z)-2-(2-arylethenyl)arylcarboxylic acids
US4929635 *3 avr. 198529 mai 1990Laboratoires Chauvin-BlacheNew derivatives of 4-vinyl benzoic acid, process for their preparation and their uses in therapeutics and as ligands
US4992468 *26 juil. 198912 févr. 1991Allergan, Inc.Phenylethenyl compounds having retinoid-like activity
US5068252 *8 févr. 199126 nov. 1991Allergan, Inc.Methods of using phenylethenyl compounds having retinoid-like activity
US5264578 *14 févr. 199223 nov. 1993Allergan, Inc.Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US5324744 *22 juil. 199228 juin 1994Allergan, Inc.7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
US5324840 *11 juin 199228 juin 1994Allergan, Inc.Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
US5326898 *11 févr. 19925 juil. 1994Allergan, Inc.Substituted phenylethenyl compounds having retinoid-like biological activity
US5344959 *18 mai 19936 sept. 1994Allergan, Inc.Tetrahydronaphthyl and cyclopropyl substituted 1,3-butadienes having retinoid-like activity
US5346895 *6 janv. 199313 sept. 1994Allergan, Inc.Chromans and thiochromans with heteroarylethynyl substituents at the 7-position having retinoid-like biological activity
US5346915 *6 janv. 199313 sept. 1994Allergan, Inc.Chromans and thiochromans with phenylethynyl substituents at the 7-position having retinold-like biological activity
US5348972 *8 mars 199320 sept. 1994Allergan, Inc.Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5348975 *27 oct. 199320 sept. 1994Allergan, Inc.7-chromanyl esters of phenols and benzoic acids having retinoid-like activity
US5349105 *17 mars 199320 sept. 1994Allergan, Inc.Alkyl, alkoxy and thioalkoxy substituted diphenyl acetylenes having retinoid like activity
US5354752 *28 oct. 199311 oct. 1994Allergan, Inc.Disubstituted acetylenes bearing a diazinyl group having retinoid like activity
US5380877 *8 mars 199310 janv. 1995Allergan, Inc.Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5391753 *27 sept. 199321 févr. 1995Allergan, Inc.Heteroaryl substituted phenylethenyl compounds having retinoid-like biological activity
US5399561 *7 janv. 199421 mars 1995Allergan, Inc.Acetylenes disubstituted with a phenyl or heteroaryl group and a 2-oxochromanyl, 2-oxothiochromanyl or 2-oxo-1,2,3,4-tetrahydro-quinolinyl group having retinoid-like biological activity
US5399586 *11 mars 199321 mars 1995Allergan, Inc.Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
US5407937 *27 oct. 199318 avr. 1995Allergan, Inc.Acetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4-tetrahydro-quinolinyl group having retinoid-like activity
US5414007 *24 sept. 19939 mai 1995Allergan, Inc.Acetylenes disubstituted with a thiazole group and a substituted phenyl group having retinoid like activity
US5426118 *30 déc. 199320 juin 1995Allergan, Inc.[4-(1,2-epoxycyclohexanyl)but-3-en-1-ynyl]aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity
US5434173 *24 sept. 199318 juil. 1995Allergan, Inc.Heteroaryl substituted phenylethenyl compounds having retinoid-like biological activity
US5451605 *30 déc. 199319 sept. 1995Allergan, Inc.1,2-epoxycyclohexanyl and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity
US5455265 *11 févr. 19933 oct. 1995Allergan, Inc.Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US5468879 *24 sept. 199321 nov. 1995Allergan, Inc.Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US5470999 *30 déc. 199328 nov. 1995Allergan, Inc.Cyclohexene and bicyclic aromatic substituted ethyne compounds having retinoid-like biological activity
US5475022 *18 oct. 199312 déc. 1995Allergan, Inc.Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity
US5475113 *15 juin 199412 déc. 1995Allergan, Inc.Tetrahydronaphthyl and thiazole, oxazole or imidazole substituted ethene derivatives having retinoid-like activity, reduced skin toxicity and reduced teratogenecity
US5489584 *29 déc. 19946 févr. 1996Allergan, Inc.Acetylenes disubstituted with a 5-amino or substituted 5-amino substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5498755 *23 août 199412 mars 1996Chandraratna; Roshantha A.Disubstituted aryl and heteroaryl imines having retinoid-like biological activity
US5514825 *29 déc. 19947 mai 1996Allergan, Inc.Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5516904 *7 févr. 199514 mai 1996Allergan, Inc.Acetylenes disubstituted with a heteroaromatic group and a substituted phenyl group having retinoid like activity
US5534516 *7 févr. 19959 juil. 1996AllerganAcetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1, 2, 3, 4-tetrahydroquinolinyl group having retinoid-like activity
US5543534 *29 déc. 19946 août 1996AllerganAcetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5556996 *29 déc. 199417 sept. 1996AllerganOxiranyls disubstituted with a phenyl group and a substituted chromanyl or tetrahydroquinolinyl group having retinoid like activity
US5591858 *27 févr. 19967 janv. 1997AllerganAcetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5599819 *2 juin 19954 févr. 1997AllerganAcetylenes disubstituted with a thienyl or furyl group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4 - tetrahydroquinolinyl group having retinoid-like activity
US5599967 *29 déc. 19944 févr. 1997AllerganAcetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity
US5602130 *14 oct. 199411 févr. 1997AllerganDisubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US5602135 *2 juin 199511 févr. 1997AllerganPhenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity
US5605915 *31 mai 199625 févr. 1997AllerganAcetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5616597 *2 juin 19951 avr. 1997AllerganAcetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1,2,3,4--tetrahydroquinolinyl group having retinoid-like activity
US5616712 *16 mai 19951 avr. 1997AllerganAcetylenes disubstituted with a phenyl or heteroaryl group and a 2-thio-1,2,3,4-tetrahdroquinolinyl, 2-alkylthio-3,4-dihydroquinolinyl or 2-alkoxy-3,4-dihydroquinolinyl group having retinoid-like biological activity
US5618836 *10 avr. 19958 avr. 1997Allergan[4-(1,2-epoxycyclohexanyl)but-3-en-1-ynyl]aromatic and heteroaromatic acids and derivatives having retinoid-like biological activity
US5618931 *29 déc. 19948 avr. 1997AllerganAcetylenes disubstituted with a 5 substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5618943 *29 déc. 19948 avr. 1997AllerganAcetylenes disubstituted with a 5 OXO substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5648503 *31 mai 199615 juil. 1997AllerganAcetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5654469 *31 mai 19965 août 1997AllerganAcetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl or heteroaryl groups having retinoid-like biological activity
US5663347 *6 juin 19952 sept. 1997AllerganDisubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US5663357 *22 nov. 19952 sept. 1997AllerganSubstituted heteroarylamides having retinoid-like biological activity
US5663367 *31 mai 19962 sept. 1997Allergan2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5672710 *3 nov. 199530 sept. 1997AllerganSulfides, sulfoxides and sulfones disubstituted with a tetrahydronaphthalenyl, chromanyl, thiochromanyl or tetrahydroquinolinyl and substituted phenyl or heteroaryl group, having retinoid-like biological activity
US5675024 *22 nov. 19957 oct. 1997AllerganAryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5675033 *6 juin 19957 oct. 1997Allergan2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5677320 *9 janv. 199714 oct. 1997AllerganPhenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity
US5677323 *29 oct. 199614 oct. 1997AllerganAcetylenes disubstituted with a heteroaromatic group and a 2-substituted chromanyl, thiochromanyl or 1, 2, 3, 4, -tetrahydroquinolinyl group having retinoid-like activity
US5677451 *6 juin 199514 oct. 1997AllerganDisubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US5688957 *29 déc. 199518 nov. 1997Allergan(3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!aryl and (3"-thioxacyclohex-1"-enyl)!-but-3'-ene-1'-ynyl!heteroaryl carboxylic acids and esters having retinoid-like biological activity
US5696162 *2 juin 19959 déc. 1997AllerganPhenyl or heteroaryl and tetrahydronaphthyl substituted diene compound having retinoid like biological activity
US5698700 *31 mai 199616 déc. 1997AllerganAcetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5723666 *21 juin 19963 mars 1998AllerganOxime substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5728846 *12 déc. 199617 mars 1998AllerganBenzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5739338 *5 nov. 199614 avr. 1998AllerganN-aryl substituted tetrahydroquinolines having retinoid agonist, retinoid antagonist or retinoid inverse agonist type biological activity
US5741896 *21 juin 199621 avr. 1998AllerganO- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5747542 *21 juin 19965 mai 1998AllerganOxo-substituted tetrahydronaphthalene derivatives having retinold and/or retinoid antagonist-like biological activity
US5750693 *19 mars 199712 mai 1998AllerganDisubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US5760276 *6 mars 19972 juin 1998AllerganAryl-and heteroarylcyclohexenyl substituted alkenes having retinoid agonist, antagonist or inverse agonist type biological activity
US5763635 *21 juin 19969 juin 1998AllerganTetrahydronaphthalene derivatives substituted in the 8 position with alkyhidene groups having retinoid and/or retinoid antagonist-like biological activity
US5780647 *25 févr. 199714 juil. 1998Allergan2,4-Pentadienoic acid derivatives having retinoid-like biological activity
US5808083 *12 mai 199715 sept. 1998AllerganAcetylenes disubstituted with a 5 alkyl, aryl or heteroaryl substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5808124 *21 juin 199615 sept. 1998AllerganO- or S-substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5817836 *12 mai 19976 oct. 1998Allergan2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5847160 *4 sept. 19978 déc. 1998AllerganAcetylenes disubstituted with 2-tetrahydropyranoxy-aryl and aryl of heteroaryl groups having retinoid-like biological activity
US5856490 *4 sept. 19975 janv. 1999AllerganAryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US5917048 *19 mars 199729 juin 1999Allergan Sales Inc.Substituted aryl or heteroarylamides having retinoid-like biological activity
US5917082 *20 août 199729 juin 1999Allergan Sales, Inc.2,4-pentadienoic acid derivatives having retinoid-like biological activity
US5919970 *24 avr. 19976 juil. 1999Allergan Sales, Inc.Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US5952345 *9 juin 199714 sept. 1999Allergan Sales, Inc.Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5958954 *24 déc. 199728 sept. 1999Allergan Sales, Inc.Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5998471 *11 août 19987 déc. 1999Allergan Sales, Inc.Acetylenes disubstituted with a 5 alkyl, aryl or heteroaryl substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like biological activity
US5998655 *25 févr. 19987 déc. 1999Vuligonda; VidyasagarAlkylidene substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US6008204 *30 déc. 199828 déc. 1999Allergan Sales, Inc.Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6025388 *26 avr. 199515 févr. 2000Allergan Sales, Inc.Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US6034242 *2 oct. 19987 mars 2000Allergan Sales, Inc.2,4-pentadienoic acid derivatives having retinoid-like biological activity
US6037488 *19 avr. 199714 mars 2000Allergan Sales, Inc.Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US6051713 *17 déc. 199818 avr. 2000Allergan Sales, Inc.Substituted aryl or heteroarylamides having retinoid-like biological activity
US6051731 *4 sept. 199718 avr. 2000Allergan Sales, Inc.O-or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US6087505 *25 févr. 199811 juil. 2000Allergan Sales, Inc.Benzo[1,2-G]-chrom-3-ene, and benzo[1,2-G]-thiochrom-3-ene derivatives
US6090810 *30 déc. 199818 juil. 2000Allergan Sales, Inc.Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6090826 *25 févr. 199818 juil. 2000Allergan Sales, Inc.Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US6114533 *7 sept. 19995 sept. 2000Allergan Sales, Inc.2,4-pentadienoic acid derivatives having retinoid-like biological activity
US6117987 *8 avr. 199812 sept. 2000Allergan Sales, Inc.Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist like biological activity
US6124455 *25 janv. 200026 sept. 2000Allergan Sales, Inc.Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US617211512 janv. 19989 janv. 2001Allergan Sales, Inc.Method for preventing onset of restenosis after angioplasty employing an RXR-specific retinoid
US618793327 janv. 200013 févr. 2001Allergan Sales, Inc.O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US618795012 mars 199913 févr. 2001Tae K. SongSubstituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological
US621812817 mars 199817 avr. 2001Allergan Sales, Inc.Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US622549416 sept. 19991 mai 2001Allergan Sales, Inc.Trisubstituted phenyl derivatives having retinoid agonist or inverse agonist type biological activity
US622884822 nov. 19998 mai 2001Allergan, Inc.Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US623592325 janv. 200022 mai 2001Allergan Sales, Inc.Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US624578617 avr. 200012 juin 2001Allergan Sales, Inc.Substituted aryl or heteroarylamides having retinoid-like biological activity
US631310728 sept. 20006 nov. 2001Allergan Sales, Inc.Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US631316317 août 20006 nov. 2001Allergen Sales, Inc.2,4-pentadienoic acid derivatives having retinoid-like biological activity
US63200479 avr. 200120 nov. 2001Allergan Sales, Inc.Substituted aryl or heteroarylamides having retinoid-like biological activity
US63426024 août 200029 janv. 2002Allergan Sales, Inc.Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thichroman and 1,2,3,4-tetrahydroquinolinecarboxlic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity
US63444637 juil. 20005 févr. 2002Allergan Sales, Inc.Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity
US634456111 déc. 20005 févr. 2002Allergan Sales, Inc.O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US635580616 sept. 199912 mars 2002Allergen Sales, Inc.Acetylenes disubstituted with a 5 alkyl, aryl or heteroaryl substituted dihydronaphthyl group and with an aryl or heteroaryl group having retinoid-like with an aryl or heteroaryl group having retinoid-like biological activity
US636910013 janv. 20009 avr. 2002Allergan Sales, Inc.Method for inhibiting gene expression promoted by AP1 protein with RARβ selective retinoids and method for treatment of diseases and conditions with such retinoids
US636926129 août 20009 avr. 2002Allergan Sales, Inc.Compounds having activity as inhibitors of cytochrome P450RAI
US63878927 juin 200114 mai 2002Allergan Sales, Inc.Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US638795129 août 200014 mai 2002Allergan Sales, Inc.Compounds having activity as inhibitors of cytochrome P450RAI
US643712916 oct. 200120 août 2002Allergan Sales, LlcSubstituted aryl or heteroarylamides having retinoid-like biological activity
US64557018 nov. 200024 sept. 2002Allergan, Inc.Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US64656636 juil. 200115 oct. 2002Allergan, Inc.O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US646902828 mars 200122 oct. 2002Allergan, Inc.Synthesis and use of retinoid compounds having negative hormone and/or anatgonist activities
US64955527 juin 200117 déc. 2002Allergan, Inc.Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US652162423 mars 200018 févr. 2003Allergan, Inc.Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US65345449 juil. 199918 mars 2003Allergan Sales, Inc.Methods of treatment with compounds having RARα receptor specific or selective activity
US653814913 janv. 200025 mars 2003AllerganAryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo [1,2-g]chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
US65556908 mai 200229 avr. 2003Allergan, Inc.Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US661074429 nov. 200126 août 2003Allergan, Inc.Methods of treatment with compounds having RARα receptor specific or selective activity
US662418823 mars 199423 sept. 2003Allergan, Inc.Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects
US662765220 avr. 199530 sept. 2003Allergan, Inc.Method of treatment with compounds having selective agonist-like activity on RXR retinoid receptors
US665348317 avr. 200025 nov. 2003Alan T. JohnsonAlkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US66607555 août 20029 déc. 2003Allergan, Inc.Substituted diaryl or diheteroaryl methans, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US67204259 déc. 200213 avr. 2004Allergan, Inc.Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US68187759 déc. 200316 nov. 2004Allergan, Inc.Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US68555125 août 200215 févr. 2005Allergan, Inc.Methods for identifying inhibitors of cytochrome P450RAI
US685583211 oct. 200215 févr. 2005Allergan, Inc.O- or S-substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US694298010 oct. 200013 sept. 2005Allergan, Inc.Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US71667262 janv. 200323 janv. 2007Allergan, Inc.Aryl substituted 3,4-dihydroanthracene derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
US732105015 juil. 200422 janv. 2008Welichem Biotech Inc.Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
US78680473 déc. 200711 janv. 2011Welichem Biotech Inc.Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
US20030078270 *5 août 200224 avr. 2003Jayasree VasudevanMethods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US20030130515 *2 janv. 200310 juil. 2003Vidyasagar VuligondaAryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
US20030219832 *27 mai 200327 nov. 2003Klein Elliott S.Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US20040127469 *9 déc. 20031 juil. 2004Johnson Alan T.Alkyl or aryl substituted dihydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US20050059733 *15 juil. 200417 mars 2005Welichem Biotech, Inc.Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
US20080139666 *3 déc. 200712 juin 2008Welichem Biotech Inc.Anti-Inflammatory and Psoriasis Treatment and Protein Kinase Inhibition by Hydroxy Stilbenes and Novel Stilbene Derivatives and Analogues
WO1993025530A2 *1 juin 199323 déc. 1993Allergan, Inc.Vinyl arenas having retinoid-like activity
WO1993025530A3 *1 juin 199317 mars 1994Allergan IncVinyl arenas having retinoid-like activity
WO2001042231A2 *6 déc. 200014 juin 2001Welichem Biotech Inc.Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors
WO2001042231A3 *6 déc. 20001 nov. 2001Genhui ChenPolyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors
WO2013003112A119 juin 20123 janv. 2013The Jackson LaboratoryMethods and compositions for treatment of cancer and autoimmune disease
Classifications
Classification aux États-Unis560/8, 562/495, 560/104, 562/405
Classification internationaleC07C51/09, A61P35/00, C07C233/65, C07C63/66, A61K31/19, A61K31/165, C07C63/74, A61P35/02, C07C69/76, A61K31/235, C07C67/00, C07C51/00, A61K31/215
Classification coopérativeC07C63/74, C07C63/66
Classification européenneC07C63/74, C07C63/66
Événements juridiques
DateCodeÉvénementDescription
13 sept. 1988CCCertificate of correction
20 févr. 1990DIAdverse decision in interference
Effective date: 19891211
3 sept. 1991REMIMaintenance fee reminder mailed
2 févr. 1992LAPSLapse for failure to pay maintenance fees
7 avr. 1992FPExpired due to failure to pay maintenance fee
Effective date: 19920131